miR Scientific, LLC | 1 395 abonnés sur LinkedIn. miR Scientific is a healthcare company that is committed to transforming cancer management globally. | miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers.
miR Scientific, LLC is a healthcare company committed to transforming global cancer management by providing early and highly accurate detection, characterization, and monitoring of disease. The Company has developed the miR Disease Management Platform®, a proprietary, non-invasive platform for the effective management of targeted diseases, initially focused on urological cancers. The platform is powered by the miR Sentinel® Prostate Cancer Test, a liquid biopsy urine test that can accurately detect, classify, and monitor prostate cancer based on the interrogation of small-non-coding RNAs extracted from urinary exosomes. miR Scientific is developing interoperable products and services necessary to revolutionize the standards of care supporting urologic oncology, including for prostate, bladder, and other urothelial cancers. Such new standards are urgently needed given the prevalence of these cancers and their debilitating burden globally. miR Scientific is a majority-owned operating subsidiary of Impact NRS LLC, headquartered in New York City with operating subsidiaries in Israel, Canada, and Puerto Rico.
miR Scientific
miR-375 is cold exposure sensitive and drives thermogenesis in visceral adipose tissue derived stem cells
miR Scientific announces FDA Breakthrough Device Designation for its Prostate Cancer Liquid Biopsy Test
Samantha Mall - Senior Research Associate - Assay Development - miR Scientific, LLC
miR Scientific
miR Scientific, LLC
Cancers, Free Full-Text
Arminda Figueroa (@ArmindaMindy) / X
Redox-responsive nanoplatform for codelivery of miR-519c and gemcitabine for pancreatic cancer therapy
MiR-4458 inhibited cell proliferation by down-regulating STAT3. A
Molecular Diagnostic Prostate Cancer Test
